XCSFDHG46767FHJHJF
tdp2664 InvestorPlace It has been a good year for Alexion Pharmaceuticals ( NASDAQ : ALXN ) — earnings are up, its star drug Solaris is coming on strong and the company's stock is on a tear. The stock's performance has moved it to the head of the class among its peers in the biopharmaceutical niche. But does ALXN have what it takes to go the distance? Biopharmaceuticals, which are drugs created primarily from antibodies or living organisms like viruses and bacteria, are one of the most promising niches in pharmaceuticals because these drugs can treat rare and difficult conditions. ALXN's peers in the biopharmaceutical space include Amgen ( NASDAQ : AMGN ), Allergan (NYSE: AGN ) and Roche/c (PINK: RHHBY ). All investors dream of being able to predict a stock sector boom — and better yet, picking the next big winner. After all, who wouldn't have liked to say "I bought Amazon ( NASDAQ : AMZN ) back in '97 at $1.50"? Of course, for every Amazon, there were scores of two-year wonders like WebVan
No comments:
Post a Comment